The George Washington University School of Public Health and Health Services has issued a report on “Obesity Drug Measures, A Consensus Report of Considerations Regarding Pharmacologic Intervention.” The report, chaired by Christine Ferguson of the STOP Obesity Alliance, identifies three categories of interested populations: the obese and ‘well’, the obese with risk factors and the obese and sick. It recommends, inter alia, that criteria for obesity drugs should characterize individuals at different levels of health, feeling and functioning. Likewise, it recommended limited access to those individuals for whom the benefits outweighed the risks. The report also recommends an FDA-approved instrument to measure the impact of weight on quality of life as well as moving beyond the cardiometabolic-centered criteria in current use. The report recommends evaluation of other effects of obesity, such as joint pain, urinary incontinence and functional limitations, such as decreased mobility. Uniquely, the report broached the issue of drugs for use in the pediatric population, a topic not previously discussed and much in need of debate. The report is available at: http://sphhs.gwu.edu/releases/obesitydrugmeasures.pdf